Where's the next big announcement going to come from though?
Here were the highlights from their Shareholder update in early October;
• Phase 2 clinical trial (VF00102) of VF001 for venous leg ulcer healing on track for top-line resultsmid-November
• Pilot clinical study of VF001 for diabetic foot ulcer (DFU) healing under development as part of acollaboration with key US researchers
• Ocular (eye) wound care technology international patent application (PCT) filed
• Ocular orphan drug designation (ODD) application on track for submission later this year
VF001 is now dead in the water. Their early research pipeline was dependent on these results being successful.
With VF001 case closed, I ask... what is their next announcement? You only have to read the last line of the summary slide from the Conference Call Details announcement to see that there is not much ahead mate...
• Results are clear: no justification to continue further development of VF001
• Ongoing development of VF001, in all indications, halted
• Factor Therapeutics to limit further activity to maintaining intellectual property portfolio
